頁籤選單縮合
| 題 名 | 紅血球生成素用於新生兒缺氧缺血性腦病變=Erythropoietin in the Treatment of Neonatal Hypoxic Ischemic Encephalopathy |
|---|---|
| 作 者 | 蘇煜尊; 蔡慈貞; 江明洲; | 書刊名 | 藥學雜誌 |
| 卷 期 | 34:3=136 2018.09[民107.09] |
| 頁 次 | 頁85-90 |
| 分類號 | 417.517 |
| 關鍵詞 | 新生兒缺氧缺血性腦病變; 低溫療法; Therapeutic hypothermia; Erythropoietin; |
| 語 文 | 中文(Chinese) |
| 中文摘要 | 新生兒的缺氧缺血性腦病變 (hypoxic ischemic encephalopathy;HIE) 會影響新生兒 腦部甚至全身器官發展。預防 HIE 的次發性大腦神經元細胞受損為治療的主要目標: 而低溫療法,藉由降低核心體溫,進而減低代謝率、減少炎性反應,可降低新生兒中 重度 HIE 的罹病率與死亡率。近年研究證據顯示低溫療法搭配具有神經保護功能的紅 血球生成素 (erythropoietin;EPO),可改善周產期新生兒 HIE 神經學預後。紅血球生 成素用於新生兒 HIE 的治療目前尚未納入健保給付,期望未來有更多大型試驗發表, 證實其對於 HIE 新生兒長期神經發展的療效。 |
| 英文摘要 | Neonatal hypoxic ischemic encephalopathy (HIE) is a clinical syndrome of “disturbed neurological function”in the newborn infants, which can lead to mortality or long-term disabilities. Preventing secondary neuronal damage to the brain cells is the main goal of treatment. Therapeutic hypothermia reduces core body temperature that will reduce neonatal HIE mortality and morbidity. Neuroprotective agent such as erythropoietin (EPO) has been shown to improve short-term neurological outcome. EPO for the treatment of neonatal HIE has not yet included in the National Health Insurance Reimbursement. There are several ongoing trials regarding effects of EPO. We hope that the results can provide additional data in terms of improvement of long-term neurodevelopmental outcome. |
本系統中英文摘要資訊取自各篇刊載內容。